iiinova — where your digital self keeps evolving

Stem Cell Evidence @stemcellevidence.bsky.social · 7h

🟣New from the #StemCellEvidence alert: ➡️ Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders by Pagliuca et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders by Pagliuca et al.
featured in the Stem Cell Evidence Alert - September 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 05/10/2026

🆕From the #StemCellEvidence alert: ➡️Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group by Bazarbachi et al. 🔗Link in the comments #MedSky

$Image showing a PICO summary for: Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group by Bazarbachi et al. featured in the Stem Cell Evidence Alert - September 2026$

111

Stem Cell Evidence @stemcellevidence.bsky.social · 02/10/2026

🟣 New from the #StemCellEvidence alert: 📑 Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial by Wu et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for: Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial
by Wu et al.
featured in the Stem Cell Evidence Alert - September 2026

121

Stem Cell Evidence @stemcellevidence.bsky.social · 01/10/2026

🆕 From the #StemCellEvidence alert: 📑 Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial by Jimenez Jimenez et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial
by Jimenez Jimenez et al.
featured in the Stem Cell Evidence Alert - September 2026

110

Stem Cell Evidence @stemcellevidence.bsky.social · 30/09/2026

🟣 New from the #StemCellEvidence alert: 📑 GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches by Kirshenboim et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches by Kirshenboim et al.
featured in the Stem Cell Evidence Alert - September 2026

132

Stem Cell Evidence @stemcellevidence.bsky.social · 29/09/2026

🟣 The #StemCellEvidence alert - September 2026, is out! 🔗 See the link in the comments for the top 10 articles #MedSky

Image showing an extract of the Stem Cell Evidence Alert - September 2026

121

Stem Cell Evidence @stemcellevidence.bsky.social · 03/09/2026

🟣 New from the #StemCellEvidence alert: 📑 CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results by Silbert et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results
by Silbert et al.
Link in the comments
featured in the Stem Cell Evidence Alert - July/August 2026

132

Stem Cell Evidence @stemcellevidence.bsky.social · 03/09/2026

🆕 From the #StemCellEvidence alert: 📑 CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial by Tang et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial
by Tang et al.
featured in the Stem Cell Evidence Alert - July/August 2026

132

Stem Cell Evidence @stemcellevidence.bsky.social · 02/09/2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 02/09/2026

110

Stem Cell Evidence @stemcellevidence.bsky.social · 01/09/2026

🟣 New from the #StemCellEvidence alert: 📑 Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes by Popat et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
featured in the Stem Cell Evidence Alert - July/August 2026

132

Stem Cell Evidence @stemcellevidence.bsky.social · 01/09/2026

🆕From the #StemCellEvidence alert: 📑Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A #SystematicReview of Efficacy and Toxicity by Shafqat et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity
by Shafqat et al.
featured in the Stem Cell Evidence Alert - July/August 2026

121

Stem Cell Evidence @stemcellevidence.bsky.social · 28/08/2026

🟣 New from the #StemCellEvidence alert: 📑 Incidence, molecular and clinical characteristics of donor-derived hematologic malignancies after allogeneic stem cell transplantation for myeloid malignancies by Perekhrestenko et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Incidence, molecular and clinical characteristics of donor-derived hematologic malignancies after allogeneic stem cell transplantation for myeloid malignancies
by Perekhrestenko et al.

featured in the Stem Cell Evidence Alert - July/August 2026

121

Stem Cell Evidence @stemcellevidence.bsky.social · 28/08/2026

🆕 From the #StemCellEvidence alert: 📑 Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development by Pidala et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:

featured in the Stem Cell Evidence Alert - July/August 2026

121

Stem Cell Evidence @stemcellevidence.bsky.social · 27/08/2026

🟣 New from the #StemCellEvidence alert: 📑 Donor age as a dual-risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation by Nishiwaki et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Donor age as a dual-risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
by Nishiwaki et al.
featured in the Stem Cell Evidence Alert - July/August 2026

122

Stem Cell Evidence @stemcellevidence.bsky.social · 27/08/2026

🆕 From the #StemCellEvidence alert: 📑 Evaluation of ex-utero collection for umbilical cord blood banking: A randomized clinical trial comparing cord blood quality with the in-utero technique by Ozbey et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Evaluation of ex-utero collection for umbilical cord blood banking: A randomized clinical trial comparing cord blood quality with the in-utero technique
by Ozbey et al.
featured in the Stem Cell Evidence Alert - July/August 2026

122

Stem Cell Evidence @stemcellevidence.bsky.social · 26/08/2026

🟣 New from the #StemCellEvidence alert: 📑 Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial by Ladetto et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial
by Ladetto et al.
featured in the Stem Cell Evidence Alert - July/August 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 26/08/2026

🆕 From the #StemCellEvidence alert: 📑 Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study by Li et al. 🔗 Link in the comments #MedSky

$Image showing a PICO summary for: Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study by Li et al. featured in the Stem Cell Evidence Alert - July/August 2026$

100

Stem Cell Evidence @stemcellevidence.bsky.social · 25/08/2026

📄New from the #StemCellEvidence alert: Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee by Gurnari et al. 🔗Link in the replies #MedSky

Image showing PICO summary for:
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee by Gurnari et al.
Featured in the Stem Cell Evidence Alert - August 2026

133

Stem Cell Evidence @stemcellevidence.bsky.social · 25/08/2026

📄From the #StemCellEvidence alert: High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial by Illerhaus et al. 🔗Link in the replies #MedSky

Image showing PICO summary for:
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial by Illerhaus et al.
Featured in the Stem Cell Evidence Alert - August 2026

122

Stem Cell Evidence @stemcellevidence.bsky.social · 24/08/2026

📄 From the #StemCellEvidence alert: The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy by Greco et al. 🔗 Link in the replies #MedSky

Image showing a PICO summary for:
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy by Greco et al.
Featured in the Stem Cell Evidence Alert - August 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 24/08/2026

📄 New from the #StemCellEvidence alert: Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al. 🔗 Link in the replies #MedSky

Image showing a PICO summary for:
Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al.
Featured in the Stem Cell Evidence Alert - August 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 21/08/2026

🟣 New from the #StemCellEvidence alert: 📑 Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee by Dreger et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee
by Dreger et al.
featured in the Stem Cell Evidence Alert - July/August 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 21/08/2026

🆕 From the #StemCellEvidence alert: 📑 Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status by Gang et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status
by Gang et al.
featured in the Stem Cell Evidence Alert - July/August 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 20/08/2026

🟣 New from the #StemCellEvidence alert: 📑 Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial by Bashey et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial
by Bashey et al.

featured in the Stem Cell Evidence Alert - July/August 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 20/08/2026

🆕 From the #StemCellEvidence alert: 📑 Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial by Bernaudin et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial
by Bernaudin et al.
featured in the Stem Cell Evidence Alert - July/August 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 19/08/2026

✅ New from the #StemCellEvidence alert: 📑 Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission (...) by Maffini et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
by Maffini et al.
featured in the Stem Cell Evidence Alert - July/August 2026

132

Stem Cell Evidence @stemcellevidence.bsky.social · 19/08/2026

🟣 From the #StemCellEvidence alert: 🆕 Infection Burden in Mismatched Unrelated Donor #HematopoieticCellTransplantation: Results from the ACCESS Trial by Auletta et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for the article:
Infection Burden in Mismatched Unrelated Donor #HematopoieticCellTransplantation: Results from the ACCESS Trial
by Auletta et al.
featured in the Stem Cell Evidence Alert - July/August 2026

122

Stem Cell Evidence @stemcellevidence.bsky.social · 18/08/2026

🆕 The #StemCellEvidence alert for July/August is out! 🟣 See link in the comments.

Image showing an extract of the Stem Cell Evidence Alert - July/August 2026

132

Stem Cell Evidence @stemcellevidence.bsky.social · 13/07/2026

🆕 From the #StemCellEvidence alert: 📑 Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review by Wang et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review
by Wang et al.
featured in the Stem Cell Evidence Alert - June 2026

122

Stem Cell Evidence @stemcellevidence.bsky.social · 10/07/2026

🆕 From the #StemCellEvidence alert: 📑 PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data by Rodriguez-Rodriguez et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data
by Rodriguez-Rodriguez et al.
featured in the Stem Cell Evidence Alert - June 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 09/07/2026

🆕 From the #StemCellEvidence alert: 📑 Comparative efficacy and safety of antifungal prophylactic agents in allogeneic hematopoietic stem cell transplantation: A #systematicreview and network #meta-analysis by Li et al. 🔗 Link in the comments

Image showing a PICO summary for:

featured in the Stem Cell Evidence Alert - June 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 08/07/2026

✅ From the #StemCellEvidence alert: 📑 The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units by Lee et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units
by Lee et al.
featured in the Stem Cell Evidence Alert - June 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 07/07/2026

🆕 From the #StemCellEvidence alert: 📑 Cord Blood Transplantation versus Other Donor Sources in High-Risk Acute Myeloid Leukemia by Hirao et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Cord Blood Transplantation versus Other Donor Sources in High-Risk Acute Myeloid Leukemia
by Hirao et al.
featured in the Stem Cell Evidence Alert - June 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 06/07/2026

✅From the #StemCellEvidence alert: 📑Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT by Furnari et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT
by Furnari et al.

featured in the Stem Cell Evidence Alert - June 2026

122

Stem Cell Evidence @stemcellevidence.bsky.social · 03/07/2026

🆕 From the #StemCellEvidence alert: 📑 A Network #Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation by Bentolila et al. 🔗 Link in the comments #MedSky

Image showing a PICO summary for:
A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation
by Bentolila et al.
featured in the Stem Cell Evidence Alert - June 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 02/07/2026

🆕 From the #StemCellEvidence alert: 📑Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation by Balas et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation
by Balas et al.
featured in the Stem Cell Evidence Alert - June 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 01/07/2026

✅ New from the #StemCellEvidence alert: 📑Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with #sicklecelldisease by Alasbali et al 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with #sicklecelldisease
by Alasbali et al.
featured in the Stem Cell Evidence Alert - June 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 30/06/2026

🟣New from the #StemCellEvidence alert: 📑Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE) (...) by Dreyling et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
by Dreyling et al.

featured in the Stem Cell Evidence Alert - June 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 29/06/2026

🆕The latest #StemCellEvidence alert is out! 🟣See the top 10 articles in the #StemCell Evidence Alert - June 2026. Each one has an easy-to-read PICO summary. 🔗Link in the comments #MedSky

Image showing an extract of the Stem Cell Evidence Alert - June 2026

112

Stem Cell Evidence @stemcellevidence.bsky.social · 11/06/2026

New from the #StemCellEvidence alert Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment by Schoettler et al. Link in the comments #MedSky

Image showing a PICO summary for:
Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment
by Schoettler et al.
featured in the Stem Cell Evidence Alert - May 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 10/06/2026

From the #StemCellEvidence alert: Extended HLA Haplotypes and Transplant Survival by Petersdorf et al. Link in the comments #MedSky

Image showing a PICO summary for:
Extended HLA Haplotypes and Transplant Survival
by Petersdorf et al.
featured in the Stem Cell Evidence Alert - May 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 09/06/2026

New from the #StemCellEvidence alert: Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study by Nickel et al. Link in the comments #MedSky

Image showing a PICO summary for:
Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study
by Nickel et al.

featured in the Stem Cell Evidence Alert - May 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 08/06/2026

From the #StemCellEvidence alert: Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes by Negishi et al. Link in the comments #MedSky

Image showing a PICO summary for:
Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes
by Negishi et al.
featured in the Stem Cell Evidence Alert - May 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 05/06/2026

New from the #StemCellEvidence alert: Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age by Mehta et al. Link in the comments

Image showing a PICO summary for:
Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age
by Mehta et al.
featured in the Stem Cell Evidence Alert - May 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 04/06/2026

From the #StemCellEvidence alert: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study by Hansen et al. 🔗 Link in the comments #MedSky

$Image showing a PICO summary for: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study by Hansen et al. featured in the Stem Cell Evidence Alert - May 2026$

112

Stem Cell Evidence @stemcellevidence.bsky.social · 03/06/2026

From the #StemCellEvidence alert: Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial by Gay et al. 🔗Link in the comments #MedSky

Image showing a PICO summary for:
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
by Gay et al.

featured in the Stem Cell Evidence Alert - May 2026

100

Stem Cell Evidence @stemcellevidence.bsky.social · 02/06/2026

New from the #StemCellEvidence alert: Ciprofloxacin prophylaxis in allogeneic haematopoietic cell transplantation reduces bacteraemia but increases antimicrobial resistance without improving patient outcomes by Baltas et al. Link in the comments #MedSky

Image showing a PICO summary for:
Ciprofloxacin prophylaxis in allogeneic haematopoietic cell transplantation reduces bacteraemia but increases antimicrobial resistance without improving patient outcomes
by Baltas et al.
featured in the Stem Cell Evidence Alert - May 2026

111

Stem Cell Evidence @stemcellevidence.bsky.social · 01/06/2026

From the #StemCellEvidence alert: Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia by Arai et al. Link in the comments #MedSky #StemCellResearch

$Image showing a PICO summary for: Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia by Arai et al. featured in the Stem Cell Evidence Alert - May 2026$

111

Stem Cell Evidence @stemcellevidence.bsky.social · 29/05/2026

New from the #StemCellEvidence alert: Base Editing of HBG1 and HBG2 Promoters for #SickleCellDisease by Gupta et al. Link in the comments #MedSky #StemCellResearch

Image showing a PICO summary for:
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
by Gupta et al.
featured in the Stem Cell Evidence Alert - May 2026

110